<DOC>
	<DOCNO>NCT00003281</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness topotecan paclitaxel treat patient recurrent refractory small cell lung cancer .</brief_summary>
	<brief_title>Topotecan Paclitaxel Treating Patients With Recurrent Refractory Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine toxicity combination topotecan paclitaxel previously treat patient small cell lung cancer . - Determine response rate survival patient treat regimen . OUTLINE : This multicenter study . Patients stratify accord length time since prior treatment ( le 3 month ( stratum A ) v 3 month ( stratum B ) ) . Stratum A closed accrual effective 06/20/2000 . Patients receive topotecan IV 30 minute day 1-3 paclitaxel IV 3 hour day 3 . Courses repeat every 4 week . Patients achieve partial response stable disease continue treatment absence complete response disease progression . Patients develop disease progression CNS receive whole brain radiotherapy continue treatment . Patients achieve complete remission receive maximum 6 course treatment . Patients may undergo prophylactic cranial irradiation and/or thoracic radiotherapy discretion attend physician . Patients follow every 3 month 2 year 3 year study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Stratum A ( less 3 month since prior therapy ) close accrual effective 06/20/2000 ) Histologically cytologically confirm recurrent refractory small cell lung cancer Only 1 prior regimen allow ( alternate regimen cyclophosphamide/doxorubicin/vincristine etoposide/cisplatin acceptable ) No mixed histology Measurable evaluable disease field prior radiotherapy No uncontrolled CNS metastasis ( treat CNS metastasis eligible ) PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Hematopoietic : Absolute neutrophil count least 2,000/mm^3 Platelet count least 100,000/mm^3 Hepatic : Total bilirubin great 1.5 time upper limit normal ( ULN ) OR Direct bilirubin normal Renal : Creatinine great 1.5 time ULN Cardiovascular : No unstable angina pectoris No uncontrolled congestive heart failure No myocardial infarction within past 3 month Other : No uncontrolled infection No concurrent malignancy except skin cancer localize prostate cancer Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No prior topoisomerase I inhibitor ( e.g. , topotecan irinotecan ) taxane ( e.g. , paclitaxel docetaxel ) At least 3 month since prior chemotherapy Radiotherapy : See Disease Characteristics At least 2 week since prior radiotherapy No concurrent radiotherapy Surgery : At least 3 week since prior major surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>recurrent small cell lung cancer</keyword>
</DOC>